Drug intelligence / Profile preview

lutetium (177Lu) rhPSMA-10.1

Development stage: Phase 2
Lead developer: Blue Earth Therapeutics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lutetium (177Lu) rhPSMA-10.1 is a next-generation radiopharmaceutical therapy designed for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). It consists of a radiohybrid ligand (rhPSMA-10.1) that selectively targets the prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells, and is labeled with the beta-emitting radioisotope Lutetium-177. This targeted approach allows for precise delivery of radiation to tumor cells while minimizing exposure to healthy tissues[3][5][7]. Preclinical and early clinical data indicate that 177Lu-rhPSMA-10.1 achieves high tumor uptake and retention with favorable dosimetry profiles compared to earlier PSMA-targeted radioligands[3][4][7]. The drug is being developed by Blue Earth Therapeutics as an innovative option for patients who have progressed after other therapies.

Other names: lutetium Lu 177 PSMA-10.1lutetium Lu 177 tezuvotide tetraxetan

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on lutetium (177Lu) rhPSMA-10.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium (177Lu) rhPSMA-10.1.

Explore the full profile